In the BioHarmony Drug Report Database

"Preview" Icon

Zanubrutinib

Brukinsa (zanubrutinib) is a small molecule pharmaceutical. Zanubrutinib was first approved as Brukinsa on 2019-11-14. It is used to treat mantle-cell lymphoma in the USA. It is known to target tyrosine-protein kinase BTK. Brukinsa’s patents are valid until 2037-08-15 (FDA).

 

Trade Name

 

Brukinsa
 

Common Name

 

zanubrutinib
 

ChEMBL ID

 

CHEMBL3936761
 

Indication

 

mantle-cell lymphoma
 

Drug Class

 

Tyrosine kinase inhibitors: Bruton's (Btk) inhibitors

Image (chem structure or protein)

Zanubrutinib structure rendering